csPCNA is a potential malignant marker for SS due to our three major findings: (1) The expression of csPCNA was observed in the malignant enriched cell fraction of SS PBMCs (viable CD4+CD26-) [42,70,71], which are characteristic of malignant cells. The gene discussed is CD4; the disease is synovial sarcoma.